Evidence map›Paper›PMID 39501301›Full record

ArticleClinical epigenetics2024

Integrative analysis based on ATAC-seq and RNA-seq reveals a novel oncogene PRPF3 in hepatocellular carcinoma.

Yi Bai, Xiyue Deng, Dapeng Chen, Shuangqing Han, Zijie Lin, Zhongmin Li, Wen Tong, Jinming Li, Tianze Wang, Xiangyu Liu and 3 more

Abstract read
In one paragraph

Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Quantifying the impact of genetic mutations on enhancer dynamics.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yi Bai *Department of Hepatobiliary Surgery, School of Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
Xiyue Deng *Tianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, 300192, China.
Dapeng Chen *Tianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, 300192, China.
Shuangqing Han *Tianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, 300192, China.
Zijie LinTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, 300192, China.
Zhongmin LiDepartment of Hepatobiliary and Pancreatic Surgery, Tianjin Nankai Hospital, Tianjin, China.
Wen TongTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, 300192, China.
Jinming LiTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, 300192, China.
Tianze WangSchool of Medicine, Nankai University, Tianjin, 300071, China.
Xiangyu LiuSchool of Medicine, Nankai University, Tianjin, 300071, China.
Zirong LiuDepartment of Hepatobiliary Surgery, School of Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
Zilin CuiDepartment of Hepatobiliary Surgery, School of Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, School of Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China. 5020200824@nankai.edu.cn.

Funding

National Natural Science Foundation of China 82372194Tianjin Health Science and Technology Project TJWJ2021ZD002
6 · The paper itself

Abstract

backgroundAssay of Transposase Accessible Chromatin Sequencing (ATAC-seq) is a high-throughput sequencing technique that detects open chromatin regions across the genome. These regions are critical in facilitating transcription factor binding and subsequent gene expression. Herein, we utilized ATAC-seq to identify key molecular targets regulating the development and progression of hepatocellular carcinoma (HCC) and elucidate the underlying mechanisms.

methodsWe first compared chromatin accessibility profiles between HCC and normal tissues. Subsequently, RNA-seq data was employed to identify differentially expressed genes (DEGs). Integrating ATAC-seq and RNA-seq data allowed the identification of transcription factors and their putative target genes associated with differentially accessible regions (DARs). Finally, functional experiments were conducted to investigate the effects of the identified regulatory factors and corresponding targets on HCC cell proliferation and migration.

resultsEnrichment analysis of DARs between HCC and adjacent normal tissues revealed distinct signaling pathways and regulatory factors. Upregulated DARs in HCC were enriched in genes related to the MAPK and FoxO signaling pathways and associated with transcription factor families like ETS and AP-1. Conversely, downregulated DARs were associated with the TGF-β, cAMP, and p53 signaling pathways and the CTCF family. Integration of the datasets revealed a positive correlation between specific DARs and DEGs. Notably, PRPF3 emerged as a gene associated with DARs in HCC, and functional assays demonstrated its ability to promote HCC cell proliferation and migration. To the best of our knowledge, this is the first report highlighting the oncogenic role of PRPF3 in HCC. Furthermore, ZNF93 expression positively correlated with PRPF3, and ChIP-seq data indicated its potential role as a transcription factor regulating PRPF3 by binding to its promoter region.

conclusionThis study provides a comprehensive analysis of the epigenetic landscape in HCC, encompassing both chromatin accessibility and the transcriptome. Our findings reveal that ZNF93 promotes the proliferation and motility of HCC cells through transcriptional regulation of a novel oncogene, PRPF3.

Indexed as

Carcinoma, HepatocellularCell ProliferationGene Expression Regulation, NeoplasticLiver NeoplasmsCell Line, TumorCell MovementChromatinChromatin Immunoprecipitation SequencingHigh-Throughput Nucleotide SequencingHumansOncogenesRNA-SeqSignal TransductionTranscription FactorsChromatinTranscription FactorsAssay of transposase accessible chromatin sequencingEpigeneticsHepatocellular carcinomaPRPF3Transcription factor

Identifiers

PMID39501301
PMCPMC11539654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.